Related Experiment Videos
The controversial 'second-look' laparotomy
Bokhman YaV1, V L Vinokurov, E I Gulo
1Department of Gynaecology, N.N. Petrov Research Institute of Oncology, St.-Petersburg, Russia.
Acta Obstetricia Et Gynecologica Scandinavica. Supplement
|January 1, 1992
Summary
Second-look relaparotomy in ovarian cancer offers significant benefits for optimizing patient treatment. These operations, performed for various indications, demonstrate clear positive significance in managing malignant ovarian tumors.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Clinical Cancer Research
Background:
- Ovarian cancer management often involves complex treatment strategies.
- Relaparotomy, or 'second-look' surgery, plays a role in assessing treatment efficacy and disease status.
Purpose of the Study:
- To evaluate the indications and clinical significance of 'second-look' relaparotomy in women with malignant ovarian tumors.
- To analyze the outcomes and complications associated with these procedures.
Main Methods:
- Retrospective analysis of data from 304 women who underwent 'second-look' operations for epithelial ovarian tumors.
- Categorization of relaparotomy indications including clinical remission, treatment assessment, non-radical surgery, suspected recurrence, and other pathologies.
- Monitoring of postoperative complications and mortality rates.
Main Results:
- 'Second-look' operations were performed for diverse reasons, including suspected recurrence (114 patients) and non-radical initial surgery (117 patients).
- Complications occurred in 9.5% of patients (29/304), with a postoperative mortality of 0.9%.
- The study highlights the positive impact of 'second-look' operations on optimizing treatment for ovarian cancer patients.
Conclusions:
- 'Second-look' relaparotomy is a valuable tool in the management of malignant ovarian tumors.
- Careful patient selection based on specific clinical indications is crucial for successful outcomes.
- The procedure, despite potential complications, offers significant benefits in optimizing therapeutic strategies.